04:03 AM EDT, 03/30/2026 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Sunday that its Phase 3 trial of its experimental drug, Camzyos, met its primary goal in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

The company said the study demonstrated a statistically significant and clinically meaningful reduction in left ventricular outflow tract gradient at 28 weeks compared with placebo.

Camzyos also showed improvements across multiple secondary endpoints, including heart function, wall thickness, symptom severity, and mitral valve performance, the company said.

The drugmaker added that the drug improved diastolic function and overall cardiac structure.